REPONEX PHARMACEUTICALS A/S: Financial statements 2018
CVR: 30082346
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
REPONEX PHARMACEUTICALS A/S (CVR 30082346) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 0 and a net result of DKK -1,256,682 compared with DKK -1,576,249 the year before. Equity in the 2018 report amounted to DKK 2,397,261. The solvency ratio was 24.7%.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -1,256,682
- Equity
- DKK 2,397,261
- Total Assets
- DKK 9,694,486
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | 0 | 0 | -1.3 mio. | 2.4 mio. | - |
| 2017 | - | -1.3 mio. | -1.6 mio. | 3.7 mio. | - |
| 2016 | - | 242 t. | -332 t. | 5.2 mio. | - |
| 2015 | - | -1.2 mio. | -934 t. | 536 t. | - |
| 2014 | 1 | -34 t. | -683 t. | 1.5 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
REPONEX PHARMACEUTICALS A/S has published its annual report for 2017. Gross profit came to DKK -1,266,822, and the net result was DKK -1,576,249.
As of May 14, 2018, Charlotte Pahl has joined the board of directors of REPONEX PHARMACEUTICALS A/S.
On May 14, 2018, the company changed its name from REPONEX PHARMACEUTICALS ApS to REPONEX PHARMACEUTICALS A/S.
About REPONEX PHARMACEUTICALS A/S
REPONEX PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named REPONEX PHARMACEUTICALS ApS and TRIFOILIUM ApS. The management consists of Christian Henrik Tange. The board consists of Christian Vinding Thomsen (chair), Troels Peter Troelsen and Charlotte Pahl. The company is owned by Pharma Equity Group A/S. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -6,570,000 compared with DKK -11,943,000 the year before. Equity in the 2025 report amounted to DKK 4,645,000.